$ALRTF
ALR Technologies SG Ltd. Stock $alrtf

$alrtf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000190359624000264 Filed on April 30, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue		$25.54K
YoY Change		978.83%
Cost Of Revenue		$22.10K
YoY Change		1778.91%
Gross Profit		$3.440K
YoY Change		188.83%
Gross Profit Margin		13.47%
Selling, General & Admin		$2.598M
YoY Change		-9.38%
% of Gross Profit		75535.64%
Research & Development		$1.404M
YoY Change		191.27%
% of Gross Profit		40822.91%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$4.817M
YoY Change		43.83%
Operating Profit		-$4.814M
YoY Change		-212.75%
Interest Expense		$2.522M
YoY Change		-60.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings		-$7.475M
YoY Change		-29.61%
Net Earnings / Revenue		-29270.5%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	632.5M shares		552.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$59.08K	$148.6K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$11.00K
Prepaid Expenses	$44.02K	$228.7K
Receivables	$41.10K
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$155.2K	$377.3K
YoY Change	-58.86%	95.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.180M	$1.054M
YoY Change	11.94%	30.8%
Accrued Expenses	$318.3K	$288.6K
YoY Change	10.29%	-10.4%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.07M	$27.09M
YoY Change	18.39%	10.54%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.07M	$27.09M
Total Long-Term Liabilities
Total Liabilities	$32.07M	$28.93M
YoY Change	10.85%	18.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.1M	-$112.6M
YoY Change	6.64%	10.41%
Common Stock	$30.91M	$28.04M
YoY Change	10.24%	1.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$31.92M	-$28.55M
YoY Change
Total Liabilities & Shareholders Equity	$155.2K	$377.3K
YoY Change	-58.86%	95.27%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income		-$7.475M
YoY Change		-29.61%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$1.622M
YoY Change		-21.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$744.7K
YoY Change		2978520.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$1.539M
YoY Change		-23.47%
NET CHANGE
Cash From Operating Activities		-$1.622M
Cash From Investing Activities
Cash From Financing Activities		$1.539M
Net Change In Cash		-$89.55K
YoY Change		-373.79%
FREE CASH FLOW
Cash From Operating Activities		-$1.622M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001930419
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022	alrt	Loss On Settlement Of Debt LossOnSettlementOfDebt		usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross		usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts		usd
CY2023	alrt	Reclassification Of Additional Paidin Capital On Exercise Of Warrants ReclassificationOfAdditionalPaidinCapitalOnExerciseOfWarrants		usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts		usd
CY2023	alrt	Issuance Of Ordinary Shares For Nonrecourse Notes Receivable IssuanceOfOrdinarySharesForNonrecourseNotesReceivable		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	alrt	Unrealized Foreign Exchange UnrealizedForeignExchange		usd
CY2021	alrt	Unrealized Foreign Exchange UnrealizedForeignExchange		usd
CY2021	alrt	Interest Accretion On Loan Payable InterestAccretionOnLoanPayable		usd
CY2021	alrt	Borrowing Costs On Loan Payable BorrowingCostsOnLoanPayable		usd
CY2022	alrt	Accrued Interest On Loan Payable AccruedInterestOnLoanPayable		usd
CY2021	alrt	Accrued Interest On Loan Payable AccruedInterestOnLoanPayable		usd
CY2023	alrt	Bonuses Settled By Issuance Of Shares BonusesSettledByIssuanceOfShares		usd
CY2021	alrt	Bonuses Settled By Issuance Of Shares BonusesSettledByIssuanceOfShares		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2021Q4	alrt	Loan Payable LoanPayable		usd
CY2021	alrt	Borrowing Costs On Loan Payables BorrowingCostsOnLoanPayables		usd
CY2022	alrt	Accrued Interest On Loan Payables AccruedInterestOnLoanPayables		usd
CY2021	alrt	Accrued Interest On Loan Payables AccruedInterestOnLoanPayables		usd
CY2021	alrt	Accreted Interest On Loan Payable One AccretedInterestOnLoanPayableOne		usd
CY2023	alrt	Grant Of Options As Consideration For Receiving Increase To Borrowing Limit On Line Of Credit Between Company And Vp Of Company GrantOfOptionsAsConsiderationForReceivingIncreaseToBorrowingLimitOnLineOfCreditBetweenCompanyAndVpOfCompany		usd
CY2021	alrt	Grant Of Options As Consideration For Receiving Increase To Borrowing Limit On Line Of Credit Between Company And Vp Of Company GrantOfOptionsAsConsiderationForReceivingIncreaseToBorrowingLimitOnLineOfCreditBetweenCompanyAndVpOfCompany		usd
CY2023	alrt	Modification Of Options Held By Ceo And Vp Of Company That Were Granted In Connection With Financing Provided To Company Notes ModificationOfOptionsHeldByCeoAndVpOfCompanyThatWereGrantedInConnectionWithFinancingProvidedToCompanyNotes		usd
CY2022	alrt	Modification Of Options Held By Ceo And Vp Of Company That Were Granted In Connection With Financing Provided To Company Notes ModificationOfOptionsHeldByCeoAndVpOfCompanyThatWereGrantedInConnectionWithFinancingProvidedToCompanyNotes		usd
CY2023	alrt	Options Exchanged For Warrants Upon Redomicile Merger OptionsExchangedForWarrantsUponRedomicileMerger		shares
CY2023	alrt	Options Exchanged For Warrants Upon Redomicile Mergerweightageaverage OptionsExchangedForWarrantsUponRedomicileMergerweightageaverage
CY2021	alrt	Options Exchanged For Warrants Upon Redomicile Merger OptionsExchangedForWarrantsUponRedomicileMerger		shares
CY2021	alrt	Options Exchanged For Warrants Upon Redomicile Mergerweightageaverage OptionsExchangedForWarrantsUponRedomicileMergerweightageaverage
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	alrt	Intrinsic Value IntrinsicValue
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2022	alrt	Weighted Average Exercise Price Beginnings WeightedAverageExercisePriceBeginnings
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2021	alrt	Weighted Average Exercise Price Beginnings WeightedAverageExercisePriceBeginnings
CY2023	alrt	Options Exchanged For Warrants OptionsExchangedForWarrants		shares
CY2023	alrt	Weighted Average Exercise Price Warrant Outstanding WeightedAverageExercisePriceWarrantOutstanding
CY2021	alrt	Options Exchanged For Warrants OptionsExchangedForWarrants		shares
CY2021	alrt	Weighted Average Exercise Price Warrant Outstanding WeightedAverageExercisePriceWarrantOutstanding
CY2022	alrt	Warrants Exercisable WarrantsExercisable		shares
CY2022	alrt	Weighted Average Exercise Price Exercisable Endings WeightedAverageExercisePriceExercisableEndings
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2021	alrt	Weighted Average Exercise Price Endings WeightedAverageExercisePriceEndings
CY2021	alrt	Warrants Exercisable WarrantsExercisable		shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued		shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2021	alrt	Intrinsic Values IntrinsicValues
CY2021	alrt	Interest Expenses On Loan Payable To Kwc InterestExpensesOnLoanPayableToKwc		usd
CY2021	alrt	Accrued Borrowing Costs Recorded In Interest Expense On Loan Payable To Kwc AccruedBorrowingCostsRecordedInInterestExpenseOnLoanPayableToKwc		usd
CY2023	alrt	Interest Expense Related To Grant Andor Modification Of Stock Options Held By Ceo And Vp Of Company Related To Financing Provided InterestExpenseRelatedToGrantAndorModificationOfStockOptionsHeldByCeoAndVpOfCompanyRelatedToFinancingProvided		usd
CY2023	alrt	Interest Expense Related To Stock Options Granted To Vp Of Company Related To Increase Of Borrowing Limit Of Line Of Credit InterestExpenseRelatedToStockOptionsGrantedToVpOfCompanyRelatedToIncreaseOfBorrowingLimitOfLineOfCredit		usd
CY2022	alrt	Interest Expense Related To Stock Options Granted To Vp Of Company Related To Increase Of Borrowing Limit Of Line Of Credit InterestExpenseRelatedToStockOptionsGrantedToVpOfCompanyRelatedToIncreaseOfBorrowingLimitOfLineOfCredit		usd
CY2023	alrt	Consulting Fees To Ceo Of Company Accrued On Line Of Credit Available To Company ConsultingFeesToCeoOfCompanyAccruedOnLineOfCreditAvailableToCompany		usd
CY2021	alrt	Salary And Bonus Paid To Ceo Of Company SalaryAndBonusPaidToCeoOfCompany		usd
CY2023	alrt	Bonus To Director Of Company Settled With Issuance Of Ordinary Shares BonusToDirectorOfCompanySettledWithIssuanceOfOrdinaryShares		usd
CY2021	alrt	Bonus To Director Of Company Settled With Issuance Of Ordinary Shares BonusToDirectorOfCompanySettledWithIssuanceOfOrdinaryShares		usd
CY2021	alrt	Salary For Services As Secretary And Chief Legal Counsel Of Company SalaryForServicesAsSecretaryAndChiefLegalCounselOfCompany		usd
CY2021	alrt	Selling General And Administrative Expenses Related To Stock Options Granted To Chief Legal Counsel Of Company SellingGeneralAndAdministrativeExpensesRelatedToStockOptionsGrantedToChiefLegalCounselOfCompany		usd
CY2023	alrt	Loss On Settlement Of Debt To Relative Of Ceo Of Company LossOnSettlementOfDebtToRelativeOfCeoOfCompany		usd
CY2022	alrt	Loss On Settlement Of Debt To Relative Of Ceo Of Company LossOnSettlementOfDebtToRelativeOfCeoOfCompany		usd
CY2022	alrt	Consulting Fees To Relative Of Ceo Of Company ConsultingFeesToRelativeOfCeoOfCompany		usd
CY2021	alrt	Consulting Fees To Relative Of Ceo Of Company ConsultingFeesToRelativeOfCeoOfCompany		usd
CY2023	alrt	Rent Paid To Company Controlled By Vp And Immediate Family Members RentPaidToCompanyControlledByVpAndImmediateFamilyMembers		usd
CY2023	alrt	Income Tax Provision IncomeTaxProvision		usd
CY2022	alrt	Income Tax Provision IncomeTaxProvision		usd
CY2021	alrt	Income Tax Provision IncomeTaxProvision		usd
CY2023	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes		usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes		usd
CY2021	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes		usd
CY2022	alrt	Reclassification Of Additional Paidin Capital On Exercise Of Stock Options And Warrants ReclassificationOfAdditionalPaidinCapitalOnExerciseOfStockOptionsAndWarrants		usd
CY2022	alrt	Options Exercised For Settlement Of Debt OptionsExercisedForSettlementOfDebt		usd
CY2021	alrt	Options Exercised For Settlement Of Debt OptionsExercisedForSettlementOfDebt		usd
CY2022	alrt	Ordinary Shares Issued To Retire Interest Payable And Promissory Notes Payable OrdinarySharesIssuedToRetireInterestPayableAndPromissoryNotesPayable		usd
CY2023	alrt	Additional Paidin Capital On Kwc Loan Payable AdditionalPaidinCapitalOnKwcLoanPayable		usd
CY2021	alrt	Additional Paidin Capital On Kwc Loan Payable AdditionalPaidinCapitalOnKwcLoanPayable		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56491
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALR Technologies SG Ltd.
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	SINGAPORE
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9 Raffles Place
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	#26-01 Republic Plaza
CY2023	dei	Entity Address Country EntityAddressCountry	SG
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	048619
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	U0
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	632466844	shares
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Name AuditorName	DALE MATHESON CARR-HILTON LABONTE LLP
CY2023	dei	Auditor Location AuditorLocation	Vancouver, Canada
CY2023	dei	Auditor Firm AuditorFirmId	1173
CY2023Q4	us-gaap	Cash Cash	59082	usd
CY2022Q4	us-gaap	Cash Cash	148628	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41100	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44016	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	228661	usd
CY2023Q4	us-gaap	Assets Assets	155198	usd
CY2022Q4	us-gaap	Assets Assets	377289	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1501322	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1342872	usd
CY2023Q4	alrt	Notes Payable Related Parties Classified Current Two NotesPayableRelatedPartiesClassifiedCurrentTwo	3091966	usd
CY2022Q4	alrt	Notes Payable Related Parties Classified Current Two NotesPayableRelatedPartiesClassifiedCurrentTwo	3091966	usd
CY2021	alrt	Loss On Settlement Of Debt LossOnSettlementOfDebt	-33614	usd
CY2023	alrt	Other Items Amount OtherItemsAmount	-2660543	usd
CY2022	alrt	Other Items Amount OtherItemsAmount	-6350401	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2163368	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2163368	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5170149	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4662731	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	17956033	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	15828155	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2188515	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32071353	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27089092	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	1842982	usd
CY2023Q4	us-gaap	Liabilities Liabilities	32071353	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28932074	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	30912769	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	28040825	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57280320	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56032129	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-844	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6147	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120108400	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112633886	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-31916155	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28554785	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155198	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	377289	usd
CY2023	us-gaap	Revenues Revenues	25536	usd
CY2022	us-gaap	Revenues Revenues	2367	usd
CY2021	us-gaap	Revenues Revenues	7468	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	22096	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1176	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2523	usd
CY2023	us-gaap	Gross Profit GrossProfit	3440	usd
CY2022	us-gaap	Gross Profit GrossProfit	1191	usd
CY2021	us-gaap	Gross Profit GrossProfit	4945	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1404308	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	482141	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	498996	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	814677	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	920208	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	881016	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2598426	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2867250	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1566306	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4817411	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4269599	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2946318	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4813971	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4268408	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-2941373	usd
CY2023	us-gaap	Interest Expense InterestExpense	2521543	usd
CY2022	us-gaap	Interest Expense InterestExpense	6350401	usd
CY2021	us-gaap	Interest Expense InterestExpense	5468328	usd
CY2023	alrt	Loss On Settlement Of Debt LossOnSettlementOfDebt	-139000	usd
CY2022	alrt	Share Based Compensation Professional Fees ShareBasedCompensationProfessionalFees	38614	usd
CY2021	alrt	Other Items Amount OtherItemsAmount	-5501942	usd
CY2023	alrt	Net Loss NetLoss	-7474514	usd
CY2022	alrt	Net Loss NetLoss	-10618809	usd
CY2021	alrt	Net Loss NetLoss	-8443315	usd
CY2023	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	-6991	usd
CY2022	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	17556	usd
CY2021	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	-11409	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-7481505	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-10601253	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-8454724	usd
CY2023	alrt	Weighted Average Number Of Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfOrdinarySharesOutstandingBasicAndDiluted	581016295	shares
CY2022	alrt	Weighted Average Number Of Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfOrdinarySharesOutstandingBasicAndDiluted	548078686	shares
CY2021	alrt	Weighted Average Number Of Ordinary Shares Outstanding Basic And Diluted WeightedAverageNumberOfOrdinarySharesOutstandingBasicAndDiluted	534980347	shares
CY2023	alrt	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.01
CY2022	alrt	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.02
CY2021	alrt	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.02
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-21760608	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	250800	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1124832	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2021	alrt	Imputed Interest ImputedInterest	112339	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4403218	usd
CY2021	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	-11409	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8443315	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-24312143	usd
CY2022	alrt	Issuance Of Ordinary Shares For Settlement Of Debt And Bonuses IssuanceOfOrdinarySharesForSettlementOfDebtAndBonuses	370000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25	usd
CY2022	alrt	Imputed Interest ImputedInterest	104494	usd
CY2022	alrt	Discount On Loan Payable DiscountOnLoanPayable	113912	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5770180	usd
CY2022	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	17556	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10618809	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-28554785	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-28554785	usd
CY2023	alrt	Issuance Of Ordinary Shares For Settlement Of Debt And Prepaid Expenses IssuanceOfOrdinarySharesForSettlementOfDebtAndPrepaidExpenses	375000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	744655	usd
CY2023	alrt	Exercise Of Warrants ExerciseOfWarrants	24000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75000	usd
CY2023	alrt	Imputed Interest ImputedInterest	34431	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2867049	usd
CY2023	alrt	Exchange Difference On Translating Foreign Operations ExchangeDifferenceOnTranslatingForeignOperations	-6991	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7474514	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-31916155	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7474514	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10618809	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8443315	usd
CY2023	alrt	Share Based Compensation Product Development Costs ShareBasedCompensationProductDevelopmentCosts	1060636	usd
CY2022	alrt	Share Based Compensation Product Development Costs ShareBasedCompensationProductDevelopmentCosts	227338	usd
CY2021	alrt	Share Based Compensation Product Development Costs ShareBasedCompensationProductDevelopmentCosts	222178	usd
CY2023	alrt	Sharebased Compensationselling General And Administrative SharebasedCompensationsellingGeneralAndAdministrative	1402533	usd
CY2022	alrt	Sharebased Compensationselling General And Administrative SharebasedCompensationsellingGeneralAndAdministrative	1499322	usd
CY2021	alrt	Sharebased Compensationselling General And Administrative SharebasedCompensationsellingGeneralAndAdministrative	586538	usd
CY2023	alrt	Share Based Compensation Professional Fees ShareBasedCompensationProfessionalFees	403880	usd
CY2021	alrt	Share Based Compensation Professional Fees ShareBasedCompensationProfessionalFees	169382	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4004906	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3425120	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	139000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	33614	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	1644027	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	1596667	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	1402187	usd
CY2023	alrt	Noncash Imputed Interest Expenses NoncashImputedInterestExpenses	34431	usd
CY2022	alrt	Noncash Imputed Interest Expenses NoncashImputedInterestExpenses	104494	usd
CY2021	alrt	Noncash Imputed Interest Expenses NoncashImputedInterestExpenses	112339	usd
CY2023	alrt	Unrealized Foreign Exchange UnrealizedForeignExchange	35827	usd
CY2023	alrt	Interest Accretion On Loan Payable InterestAccretionOnLoanPayable	48020	usd
CY2022	alrt	Interest Accretion On Loan Payable InterestAccretionOnLoanPayable	23315	usd
CY2023	alrt	Borrowing Costs On Loan Payable BorrowingCostsOnLoanPayable	150010	usd
CY2022	alrt	Borrowing Costs On Loan Payable BorrowingCostsOnLoanPayable	72834	usd
CY2023	alrt	Accrued Interest On Loan Payable AccruedInterestOnLoanPayable	111676	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	310603	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	496081	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	456725	usd
CY2022	alrt	Bonuses Settled By Issuance Of Shares BonusesSettledByIssuanceOfShares	245000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41100	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	201645	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-151366	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-14636	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	452450	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	337326	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	211012	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	531418	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	542834	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	527336	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1621664	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2573606	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2224970	usd
CY2023	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	794454	usd
CY2022	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	727986	usd
CY2021	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	1149279	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	744655	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1136832	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	1779250	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	649708	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	649708	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1539109	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2507261	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2286111	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6991	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99051	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-11409	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-89546	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32706	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	49732	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148628	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115922	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66190	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59082	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148628	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115922	usd
CY2022	alrt	Transferred From Lines Of Credit Interest TransferredFromLinesOfCreditInterest	9250	usd
CY2022Q4	alrt	Interest Payable InterestPayable	4662731	usd
CY2023	alrt	Interest Incurred On Promissory Notes Payable InterestIncurredOnPromissoryNotesPayable	531418	usd
CY2023	alrt	Transferred From Lines Of Credit Interest TransferredFromLinesOfCreditInterest	-24000	usd
CY2023Q4	alrt	Interest Payable InterestPayable	5170149	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_z05e8SLqDmAl" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <span id="xdx_869_zMfuyYjMCYze">Use of estimates</span></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, the measurement of share-based compensation, the fair value of financial instruments, the fair value of loan payable, and the reported amounts of revenues and expenses during the reporting period. Management believes the estimates are reasonable; however, actual results could differ from those estimates.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	alrt	Ordinaryshares Ordinaryshares	36000000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	5600471500	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	5522201500	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	5497001500	shares
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1180132	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1054285	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	318285	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	288587	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2905	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1501322	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1342872	usd
CY2023	alrt	Proceeds Received ProceedsReceived	26880	usd
CY2022Q4	alrt	Notes Payable Related Parties Classified Current One NotesPayableRelatedPartiesClassifiedCurrentOne	3041966	usd
CY2023	alrt	Promissory Notes Received PromissoryNotesReceived	405350	usd
CY2023	alrt	Repayment Of Promissory Notes RepaymentOfPromissoryNotes	-405350	usd
CY2023	alrt	Transferred From Promissory Notes Payable Pursuant To Private Transaction TransferredFromPromissoryNotesPayablePursuantToPrivateTransaction	50000	usd
CY2023Q4	alrt	Notes Payable Related Parties Classified Current One NotesPayableRelatedPartiesClassifiedCurrentOne	3091966	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	3091966	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	3091966	usd
CY2022Q4	alrt	Promissory Notes Payable PromissoryNotesPayable	2213368	usd
CY2023	alrt	Promissory Notes Received One PromissoryNotesReceivedOne	244358	usd
CY2023	alrt	Repayment Of Promissory Notes One RepaymentOfPromissoryNotesOne	-244358	usd
CY2023	alrt	Transferred To Promissory Notes Payable Pursuant To Private Transaction One TransferredToPromissoryNotesPayablePursuantToPrivateTransactionOne	-50000	usd
CY2023Q4	alrt	Promissory Notes Payable PromissoryNotesPayable	2163368	usd
CY2023Q4	alrt	Promissory Notes Payables PromissoryNotesPayables	2163368	usd
CY2022Q4	alrt	Promissory Notes Payables PromissoryNotesPayables	2163368	usd
CY2021Q4	alrt	Interest Payable InterestPayable	4110647	usd
CY2022	alrt	Interest Incurred On Promissory Notes Payable InterestIncurredOnPromissoryNotesPayable	542834	usd
CY2023Q4	alrt	Related Parties Payable RelatedPartiesPayable	1848079	usd
CY2022Q4	alrt	Related Parties Payable RelatedPartiesPayable	1534006	usd
CY2023Q4	alrt	Unrelated Parties Payable UnrelatedPartiesPayable	3322070	usd
CY2022Q4	alrt	Unrelated Parties Payable UnrelatedPartiesPayable	3128725	usd
CY2023Q4	alrt	Interest Payable Net InterestPayableNet	5170149	usd
CY2022Q4	alrt	Interest Payable Net InterestPayableNet	4662731	usd
CY2022	alrt	Loan Proceeds Received LoanProceedsReceived	1779250	usd
CY2022	alrt	Proceeds Allocated To Additional Paidin Capital As Benefit ProceedsAllocatedToAdditionalPaidinCapitalAsBenefit	-113912	usd
CY2022	alrt	Accreted Interest On Loan AccretedInterestOnLoan	23315	usd
CY2022	alrt	Borrowing Cost Recorded In Interest Expense BorrowingCostRecordedInInterestExpense	72834	usd
CY2022	alrt	Foreign Exchange Adjustment ForeignExchangeAdjustment	81495	usd
CY2022Q4	alrt	Loan Payable LoanPayable	1842982	usd
CY2023	alrt	Accreted Interest On Loan AccretedInterestOnLoan	48020	usd
CY2023	alrt	Borrowing Cost Recorded In Interest Expense BorrowingCostRecordedInInterestExpense	150010	usd
CY2023	alrt	Accrued Interest Recorded In Interest Expense AccruedInterestRecordedInInterestExpense	111676	usd
CY2023	alrt	Foreign Exchange Adjustment ForeignExchangeAdjustment	35827	usd
CY2023Q4	alrt	Loan Payable LoanPayable	2188515	usd
CY2023	alrt	Lines Of Credit Payable LinesOfCreditPayable	1644027	usd
CY2022	alrt	Lines Of Credit Payable LinesOfCreditPayable	1596667	usd
CY2021	alrt	Lines Of Credit Payable LinesOfCreditPayable	1402187	usd
CY2023	alrt	Promissory Notes Notes PromissoryNotesNotes	531418	usd
CY2022	alrt	Promissory Notes Notes PromissoryNotesNotes	542834	usd
CY2021	alrt	Promissory Notes Notes PromissoryNotesNotes	527336	usd
CY2023	alrt	Borrowing Costs On Loan Payables BorrowingCostsOnLoanPayables	150010	usd
CY2022	alrt	Borrowing Costs On Loan Payables BorrowingCostsOnLoanPayables	72834	usd
CY2023	alrt	Accrued Interest On Loan Payables AccruedInterestOnLoanPayables	111676	usd
CY2023	alrt	Accreted Interest On Loan Payable One AccretedInterestOnLoanPayableOne	48020	usd
CY2022	alrt	Accreted Interest On Loan Payable One AccretedInterestOnLoanPayableOne	23315	usd
CY2023	alrt	Calculation Of Imputed Interest On Promissory Notes Payable Which Had No Stated Interest Rate CalculationOfImputedInterestOnPromissoryNotesPayableWhichHadNoStatedInterestRate	34431	usd
CY2022	alrt	Calculation Of Imputed Interest On Promissory Notes Payable Which Had No Stated Interest Rate CalculationOfImputedInterestOnPromissoryNotesPayableWhichHadNoStatedInterestRate	104494	usd
CY2021	alrt	Calculation Of Imputed Interest On Promissory Notes Payable Which Had No Stated Interest Rate CalculationOfImputedInterestOnPromissoryNotesPayableWhichHadNoStatedInterestRate	112339	usd
CY2023	alrt	Other Item OtherItem	1961	usd
CY2022	alrt	Other Item OtherItem	5351	usd
CY2021	alrt	Other Item OtherItem	1346	usd
CY2022	alrt	Grant Of Options As Consideration For Receiving Increase To Borrowing Limit On Line Of Credit Between Company And Vp Of Company GrantOfOptionsAsConsiderationForReceivingIncreaseToBorrowingLimitOnLineOfCreditBetweenCompanyAndVpOfCompany	4004906	usd
CY2021	alrt	Modification Of Options Held By Ceo And Vp Of Company That Were Granted In Connection With Financing Provided To Company Notes ModificationOfOptionsHeldByCeoAndVpOfCompanyThatWereGrantedInConnectionWithFinancingProvidedToCompanyNotes	3425120	usd
CY2023	alrt	Total Interest Expenses TotalInterestExpenses	2521543	usd
CY2022	alrt	Total Interest Expenses TotalInterestExpenses	6350401	usd
CY2021	alrt	Total Interest Expenses TotalInterestExpenses	5468328	usd
CY2021Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	14008833	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	727986	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	1596667	usd
CY2022	alrt	Interest Transferred To Promissory Notes Interest Payable InterestTransferredToPromissoryNotesInterestPayable	-9250	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	496081	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	15828155	usd
CY2023	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	794454	usd
CY2023	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	1644027	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	310603	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	17956033	usd
CY2023Q4	alrt	Borrowing Limit BorrowingLimit	14300000	usd
CY2023Q4	alrt	Principal Borrowed PrincipalBorrowed	14210845	usd
CY2023Q4	alrt	Accuredinterest Accuredinterest	3745188	usd
CY2023Q4	alrt	Outstanding Amount OutstandingAmount	17956033	usd
CY2022Q4	alrt	Borrowing Limit BorrowingLimit	14300000	usd
CY2022Q4	alrt	Principal Borrowed PrincipalBorrowed	13416391	usd
CY2022Q4	alrt	Accuredinterest Accuredinterest	2411764	usd
CY2022Q4	alrt	Outstanding Amount OutstandingAmount	15828155	usd
CY2023Q4	us-gaap	Accounts Payable Fair Value Disclosure AccountsPayableFairValueDisclosure	194186	usd
CY2023	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties	20000	usd
CY2023	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1	3000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	321700000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.043
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5497001500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.006
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5362701500	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.004
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	120270000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.050
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	115500000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.050
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	165000000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.050
CY2022	alrt	Options Exchanged For Warrants Upon Redomicile Merger OptionsExchangedForWarrantsUponRedomicileMerger	-5200501500	shares
CY2022	alrt	Options Exchanged For Warrants Upon Redomicile Mergerweightageaverage OptionsExchangedForWarrantsUponRedomicileMergerweightageaverage	-0.004
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	5000000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.015
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	800000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.015
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	25000000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.050
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	90300000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.040
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	29900000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.034
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	411970000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.045
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	321700000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.043
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5497001500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.006
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	182200000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.037
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	160800000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.037
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	5221701500	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.004
CY2023	alrt	Options Outstanding OptionsOutstanding	411970000	shares
CY2023	alrt	Exercise Prices ExercisePrices	0.045
CY2022	alrt	Options Outstanding OptionsOutstanding	321700000	shares
CY2022	alrt	Exercise Prices ExercisePrices	0.043
CY2022	alrt	Intrinsic Value IntrinsicValue	0.022
CY2020	alrt	Options Outstanding OptionsOutstanding	5497001500	shares
CY2021	alrt	Exercise Prices ExercisePrices	0.006
CY2021	alrt	Intrinsic Value IntrinsicValue	0.054
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y1M17D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M15D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y4M13D
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4004906	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3425120	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1060636	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	227338	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	222178	usd
CY2023	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	403880	usd
CY2022	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	38614	usd
CY2021	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	169382	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1402533	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1499322	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	586538	usd
CY2023	alrt	Income Expense Net IncomeExpenseNet	2867049	usd
CY2022	alrt	Income Expense Net IncomeExpenseNet	5770180	usd
CY2021	alrt	Income Expense Net IncomeExpenseNet	4403218	usd
CY2023	alrt	Interest Expenses On Loan Payable To Kwc InterestExpensesOnLoanPayableToKwc	159696	usd
CY2022	alrt	Interest Expenses On Loan Payable To Kwc InterestExpensesOnLoanPayableToKwc	23315	usd
CY2023	alrt	Accrued Borrowing Costs Recorded In Interest Expense On Loan Payable To Kwc AccruedBorrowingCostsRecordedInInterestExpenseOnLoanPayableToKwc	150010	usd
CY2022	alrt	Accrued Borrowing Costs Recorded In Interest Expense On Loan Payable To Kwc AccruedBorrowingCostsRecordedInInterestExpenseOnLoanPayableToKwc	72834	usd
CY2022	alrt	Interest Expense Related To Grant Andor Modification Of Stock Options Held By Ceo And Vp Of Company Related To Financing Provided InterestExpenseRelatedToGrantAndorModificationOfStockOptionsHeldByCeoAndVpOfCompanyRelatedToFinancingProvided	4004906	usd
CY2021	alrt	Interest Expense Related To Grant Andor Modification Of Stock Options Held By Ceo And Vp Of Company Related To Financing Provided InterestExpenseRelatedToGrantAndorModificationOfStockOptionsHeldByCeoAndVpOfCompanyRelatedToFinancingProvided	1287834	usd
CY2021	alrt	Interest Expense Related To Stock Options Granted To Vp Of Company Related To Increase Of Borrowing Limit Of Line Of Credit InterestExpenseRelatedToStockOptionsGrantedToVpOfCompanyRelatedToIncreaseOfBorrowingLimitOfLineOfCredit	2137286	usd
CY2022	alrt	Consulting Fees To Ceo Of Company Accrued On Line Of Credit Available To Company ConsultingFeesToCeoOfCompanyAccruedOnLineOfCreditAvailableToCompany	124800	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0305	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.45	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.23	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	2.78	pure
CY2023	alrt	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Forfeture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateForfetureRate	0	pure
CY2022	alrt	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Forfeture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateForfetureRate	0	pure
CY2021	alrt	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Forfeture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateForfetureRate	0	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5200501500	shares
CY2023	alrt	Weighted Average Exercise Price Beginnings WeightedAverageExercisePriceBeginnings	0.004
CY2022	alrt	Options Exchanged For Warrants OptionsExchangedForWarrants	5200501500	shares
CY2022	alrt	Weighted Average Exercise Price Warrant Outstanding WeightedAverageExercisePriceWarrantOutstanding	0.004
CY2023	alrt	Warrants Exercisable WarrantsExercisable	-12000000	shares
CY2023	alrt	Weighted Average Exercise Price Exercisable Endings WeightedAverageExercisePriceExercisableEndings	-0.002
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5188501500	shares
CY2023	alrt	Weighted Average Exercise Price Endings WeightedAverageExercisePriceEndings	0.004
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5200501500	shares
CY2022	alrt	Weighted Average Exercise Price Endings WeightedAverageExercisePriceEndings	0.004
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5188501500	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.004
CY2023	alrt	Intrinsic Values IntrinsicValues	0.016
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5200501500	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.043
CY2022	alrt	Intrinsic Values IntrinsicValues	0.022
CY2023	alrt	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P0Y4M17D
CY2022	alrt	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P1Y4M17D
CY2023	alrt	Interest Expense On Lines Of Credit Payable To Ceo And Vp Of Company InterestExpenseOnLinesOfCreditPayableToCeoAndVpOfCompany	1644027	usd
CY2022	alrt	Interest Expense On Lines Of Credit Payable To Ceo And Vp Of Company InterestExpenseOnLinesOfCreditPayableToCeoAndVpOfCompany	1596667	usd
CY2021	alrt	Interest Expense On Lines Of Credit Payable To Ceo And Vp Of Company InterestExpenseOnLinesOfCreditPayableToCeoAndVpOfCompany	1402187	usd
CY2023	alrt	Interest Expense On Promissory Notes Issued To Relatives Of Ceo Of Company InterestExpenseOnPromissoryNotesIssuedToRelativesOfCeoOfCompany	328073	usd
CY2022	alrt	Interest Expense On Promissory Notes Issued To Relatives Of Ceo Of Company InterestExpenseOnPromissoryNotesIssuedToRelativesOfCeoOfCompany	324586	usd
CY2021	alrt	Interest Expense On Promissory Notes Issued To Relatives Of Ceo Of Company InterestExpenseOnPromissoryNotesIssuedToRelativesOfCeoOfCompany	316504	usd
CY2021	alrt	Consulting Fees To Ceo Of Company Accrued On Line Of Credit Available To Company ConsultingFeesToCeoOfCompanyAccruedOnLineOfCreditAvailableToCompany	249600	usd
CY2023	alrt	Salary And Bonus Paid To Ceo Of Company SalaryAndBonusPaidToCeoOfCompany	249600	usd
CY2022	alrt	Salary And Bonus Paid To Ceo Of Company SalaryAndBonusPaidToCeoOfCompany	274800	usd
CY2022	alrt	Bonus To Director Of Company Settled With Issuance Of Ordinary Shares BonusToDirectorOfCompanySettledWithIssuanceOfOrdinaryShares	40000	usd
CY2023	alrt	Salary For Services To Vp Of Company SalaryForServicesToVpOfCompany	44671	usd
CY2022	alrt	Salary For Services To Vp Of Company SalaryForServicesToVpOfCompany	43532	usd
CY2021	alrt	Salary For Services To Vp Of Company SalaryForServicesToVpOfCompany	33427	usd
CY2023	alrt	Salary For Services As Secretary And Chief Legal Counsel Of Company SalaryForServicesAsSecretaryAndChiefLegalCounselOfCompany	8934	usd
CY2022	alrt	Salary For Services As Secretary And Chief Legal Counsel Of Company SalaryForServicesAsSecretaryAndChiefLegalCounselOfCompany	8706	usd
CY2023	alrt	Selling General And Administrative Expenses Related To Stock Options Granted To Chief Legal Counsel Of Company SellingGeneralAndAdministrativeExpensesRelatedToStockOptionsGrantedToChiefLegalCounselOfCompany	84528	usd
CY2022	alrt	Selling General And Administrative Expenses Related To Stock Options Granted To Chief Legal Counsel Of Company SellingGeneralAndAdministrativeExpensesRelatedToStockOptionsGrantedToChiefLegalCounselOfCompany	304291	usd
CY2021	alrt	Loss On Settlement Of Debt To Relative Of Ceo Of Company LossOnSettlementOfDebtToRelativeOfCeoOfCompany	16800	usd
CY2023	alrt	Consulting Fees To Relative Of Ceo Of Company ConsultingFeesToRelativeOfCeoOfCompany	130000	usd
CY2022	alrt	Rent Paid To Company Controlled By Vp And Immediate Family Members RentPaidToCompanyControlledByVpAndImmediateFamilyMembers	20206	usd
CY2021	alrt	Rent Paid To Company Controlled By Vp And Immediate Family Members RentPaidToCompanyControlledByVpAndImmediateFamilyMembers	24390	usd
CY2023	alrt	Stock Options Vested To Members Of Board Of Directors And Related Parties Of Company StockOptionsVestedToMembersOfBoardOfDirectorsAndRelatedPartiesOfCompany	226329	usd
CY2022	alrt	Stock Options Vested To Members Of Board Of Directors And Related Parties Of Company StockOptionsVestedToMembersOfBoardOfDirectorsAndRelatedPartiesOfCompany	26146	usd
CY2021	alrt	Stock Options Vested To Members Of Board Of Directors And Related Parties Of Company StockOptionsVestedToMembersOfBoardOfDirectorsAndRelatedPartiesOfCompany	304692	usd
CY2023	alrt	Computed Expected Benefit Of Income Taxes ComputedExpectedBenefitOfIncomeTaxes	-1569648	usd
CY2022	alrt	Computed Expected Benefit Of Income Taxes ComputedExpectedBenefitOfIncomeTaxes	-2229950	usd
CY2021	alrt	Computed Expected Benefit Of Income Taxes ComputedExpectedBenefitOfIncomeTaxes	-1773096	usd
CY2023	alrt	Sharebased Compensation And Permanent Differences SharebasedCompensationAndPermanentDifferences	693895	usd
CY2022	alrt	Sharebased Compensation And Permanent Differences SharebasedCompensationAndPermanentDifferences	1220577	usd
CY2021	alrt	Sharebased Compensation And Permanent Differences SharebasedCompensationAndPermanentDifferences	925449	usd
CY2023	alrt	Nondeductible Interest Expense NondeductibleInterestExpense	411695	usd
CY2022	alrt	Nondeductible Interest Expense NondeductibleInterestExpense	364680	usd
CY2021	alrt	Nondeductible Interest Expense NondeductibleInterestExpense	334556	usd
CY2023	alrt	Expiry Of Tax Credits ExpiryOfTaxCredits	582939	usd
CY2022	alrt	Expiry Of Tax Credits ExpiryOfTaxCredits	525830	usd
CY2021	alrt	Expiry Of Tax Credits ExpiryOfTaxCredits	773050	usd
CY2023	alrt	True Up Of Prior Year Balances TrueUpOfPriorYearBalances	671947	usd
CY2022	alrt	True Up Of Prior Year Balances TrueUpOfPriorYearBalances	-30092	usd
CY2021	alrt	True Up Of Prior Year Balances TrueUpOfPriorYearBalances	99348	usd
CY2023	alrt	Increase Decrease In Valuation Allowance IncreaseDecreaseInValuationAllowance	-790828	usd
CY2022	alrt	Increase Decrease In Valuation Allowance IncreaseDecreaseInValuationAllowance	148955	usd
CY2021	alrt	Increase Decrease In Valuation Allowance IncreaseDecreaseInValuationAllowance	-359307	usd
CY2023	alrt	Net Operating Loss Carried Forward NetOperatingLossCarriedForward	32358315	usd
CY2022	alrt	Net Operating Loss Carried Forward NetOperatingLossCarriedForward	36124160	usd
CY2021	alrt	Net Operating Loss Carried Forward NetOperatingLossCarriedForward	35414853	usd
CY2023	alrt	Tax Rate TaxRate	0.21	pure
CY2022	alrt	Tax Rate TaxRate	0.21	pure
CY2021	alrt	Tax Rate TaxRate	0.21	pure
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	6795246	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	7586074	usd
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	7437119	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6795246	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-7586074	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-7437119	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	32358000	usd
CY2023Q4	alrt	Current And Noncurrent Asset CurrentAndNoncurrentAsset	155198	usd
CY2022Q4	alrt	Current And Noncurrent Asset CurrentAndNoncurrentAsset	377289	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25536	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2367	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7468	usd
CY2023	alrt	Net Loss NetLoss	-7474514	usd
CY2022	alrt	Net Loss NetLoss	-10618809	usd
CY2020	alrt	Net Loss NetLoss	-8443315	usd
CY2023	alrt	Reclassification Of Additional Paidin Capital On Exercise Of Stock Options And Warrants ReclassificationOfAdditionalPaidinCapitalOnExerciseOfStockOptionsAndWarrants	1653289	usd
CY2021	alrt	Reclassification Of Additional Paidin Capital On Exercise Of Stock Options And Warrants ReclassificationOfAdditionalPaidinCapitalOnExerciseOfStockOptionsAndWarrants	41271	usd
CY2023	alrt	Ordinary Shares Issued To Retire Accounts Payable OrdinarySharesIssuedToRetireAccountsPayable	294000	usd
CY2022	alrt	Ordinary Shares Issued To Retire Accounts Payable OrdinarySharesIssuedToRetireAccountsPayable	125000	usd
CY2021	alrt	Ordinary Shares Issued To Retire Accounts Payable OrdinarySharesIssuedToRetireAccountsPayable	194186	usd
CY2023	alrt	Options Exercised For Settlement Of Debt OptionsExercisedForSettlementOfDebt	75000	usd
CY2023	alrt	Ordinary Shares Issued To Retire Interest Payable And Promissory Notes Payable OrdinarySharesIssuedToRetireInterestPayableAndPromissoryNotesPayable	24000	usd
CY2021	alrt	Ordinary Shares Issued To Retire Interest Payable And Promissory Notes Payable OrdinarySharesIssuedToRetireInterestPayableAndPromissoryNotesPayable	23000	usd
CY2022	alrt	Additional Paidin Capital On Kwc Loan Payable AdditionalPaidinCapitalOnKwcLoanPayable	113912	usd

Files In Submission

Name	View Source	Status
0001903596-24-000264-index-headers.html	Edgar Link	pending
0001903596-24-000264-index.html	Edgar Link	pending
0001903596-24-000264.txt	Edgar Link	pending
0001903596-24-000264-xbrl.zip	Edgar Link	pending
alrt-001.jpg	Edgar Link	pending
alrt-002.jpg	Edgar Link	pending
alrt-20231231.xsd	Edgar Link	pending
alrt_20f.htm	Edgar Link	pending
ex10_6.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex4_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
alrt-20231231_cal.xml	Edgar Link	unprocessable
alrt-20231231_def.xml	Edgar Link	unprocessable
alrt-20231231_lab.xml	Edgar Link	unprocessable
alrt-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
alrt_20f_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALRTF
ALR Technologies SG Ltd. Stock $alrtf

2023 Q4 Form 20-F Financial Statement

#000190359624000264 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALRTF ALR Technologies SG Ltd. Stock $alrtf

2023 Q4 Form 20-F Financial Statement

#000190359624000264 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALRTF
ALR Technologies SG Ltd. Stock $alrtf